The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13729-13740

  Lee, Phong D ^a   Mukherjee, Swati ^a   Edeling, Melissa A ^b   Dowd, Kimberly A ^a   Austin S Kyle, S K ^b   Manhart, Carolyn J ^a   Diamond, Michael S ^b   Fremont, Daved H ^b   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIRUS PROTEIN;

ANTIBODY AFFINITY; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLAVIVIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MATURATION; MUTAGENESIS; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; REPLICON; SUPERNATANT; VIRION; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WEST NILE FLAVIVIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EPITOPE MAPPING; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 84888056028     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02340-13     Document Type: Article

References (75)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507.
2. Hayes EB, Gubler DJ. 2006. West Nile virus:epidemiology and clinical features of an emerging epidemic in the United States. Annu. Rev. Med. 57:181-194.
3. Sejvar JJ. 2007. The long-term outcomes of human West Nile virus infection. Clin. Infect. Dis. 44:1617-1624.
4. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, Katz N, Liljebjelke KA, Biggerstaff BJ, Fine AD, Layton MC, Mullin SM, Johnson AJ, Martin DA, Hayes EB, Campbell GL. 2001. Epidemic West Nile encephalitis, New York, 1999:results of a household-based seroepidemiological survey. Lancet 358:261-264.
5. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M. 2001. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344:1807-1814.
6. Beasley DW, Barrett AD, Tesh RB. 2013. Resurgence of West Nile neurologic disease in the United States in 2012:what happened? What needs to be done? Antiviral Res. 99:1-5.
7. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus:implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
8. Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13-22.
9. Lindenbach BD, Rice THCM. 2007. Flaviviridae:the viruses and their replication, p 1101-1152. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex:structure and maturation. Science 319:1830-1834.
11. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J. Virol. 81:6141-6145.
12. Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84:183-191.
13. Stadler K, Allison SL, Schalich J, Heinz FX. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71:8475-8481.
14. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834-1837.
15. Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG. 2004. Conformational changes of the flavivirus E glycoprotein. Structure 12:1607-1618.
16. Elshuber S, Mandl CW. 2005. Resuscitating mutations in a furin cleavage-deficient mutant of the flavivirus tick-borne encephalitis virus. J. Virol. 79:11813-11823.
17. Guirakhoo F, Heinz FX, Mandl CW, Holzmann H, Kunz C. 1991. Fusion activity of flaviviruses:comparison of mature and immature (prMcontaining) tick-borne encephalitis virions. J. Gen. Virol. 72:1323-1329.
18. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW. 2005. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 79:13262-13274.
19. Khromykh AA, Varnavski AN, Westaway EG. 1998. Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J. Virol. 72:5967-5977.
20. Kimura T, Ohyama A. 1988. Association between the pH-dependent conformational change of West Nile flavivirus E protein and virusmediated membrane fusion. J. Gen. Virol. 69:1247-1254.
21. Moesker B, Rodenhuis-Zybert IA, Meijerhof T, Wilschut J, Smit JM. 2010. Characterization of the functional requirements of West Nile virus membrane fusion. J. Gen. Virol. 91:389-393.
22. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, Keelapang P, Puttikhunt C, Perera R, Chipman PR, Kasinrerk W, Malasit P, Kuhn RJ, Sittisombut N. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84:8353-8358.
23. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC. 2006. West Nile virus discriminates between DC-SIGN and DCSIGNR for cellular attachment and infection. J. Virol. 80:1290-1301.
24. Guirakhoo F, Bolin RA, Roehrig JT. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191:921-931.
25. Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, Fikrig E, Marasco WA, Koski RA, Modis Y. 2006. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 80:11000-11008.
26. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
27. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100:6986-6991.
28. Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y. 2009. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J. Virol. 83:4338-4344.
29. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. 2006. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80:11467-11474.
30. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
31. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
32. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. 2003. Structure of West Nile virus. Science 302:248.
33. Chu JJ, Ng ML. 2004. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J. Biol. Chem. 279:54533-54541.
34. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280.
35. Lee JW, Chu JJ, Ng ML. 2006. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor αVβ3 integrin. J. Biol. Chem. 281:1352-1360.
36. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. 2003. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188:5-12.
37. Camenga DL, Nathanson N, Cole GA. 1974. Cyclophosphamidepotentiated West Nile viral encephalitis:relative influence of cellular and humoral factors. J. Infect. Dis. 130:634-641.
38. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
39. Diamond MS, Shrestha B, Mehlhop E, Sitati E, Engle M. 2003. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol. 16:259-278.
40. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-769.
41. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP. 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8:1392-1397.
42. Tesh RB, Travassos da Rosa AP, Guzman H, Araujo TP, Xiao SY. 2002. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg. Infect. Dis. 8:245-251.
43. Wang T, Anderson JF, Magnarelli LA, Wong SJ, Koski RA, Fikrig E. 2001. Immunization of mice against West Nile virus with recombinant envelope protein. J. Immunol. 167:5273-5277.
44. Colombage G, Hall R, Pavy M, Lobigs M. 1998. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:151-163.
45. Diamond MS, Pierson TC, Roehrig JT. 2012. Antibody therapeutics against flaviviruses, p 231-255. In Shi P-Y (ed), Molecular virology and control of flaviviruses. Caister Academic Press, Poole, United Kingdom.
46. Burton DR, Saphire EO, Parren PW. 2001. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260:109-143.
47. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145.
48. Klasse PJ, Moore JP. 1996. Quantitative model of antibody-and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:3668-3677.
49. Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibodymediated neutralization of animal viruses. J. Gen. Virol. 83:2091-2108.
50. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4(5):e1000060. doi:10.1371/journal.ppat.1000060.
51. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28:3269-3276.
52. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75:4040-4047.
53. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW. 2006. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346:53-65.
54. Dowd KA, Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses:a reductionist view. Virology 411:306-315.
55. Shrestha B, Austin SK, Dowd KA, Prasad AN, Youn S, Pierson TC, Fremont DH, Ebel GD, Diamond MS. 2012. Complex phenotypes in mosquitoes and mice associated with neutralization escape of a dengue virus type 1 monoclonal antibody. Virology 427:127-134.
56. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828-11839.
57. Oliphant T, Diamond MS. 2007. The molecular basis of antibodymediated neutralization of West Nile virus. Expert Opin. Biol. Ther. 7:885-892.
58. Mukherjee S, Lin TY, Dowd KA, Manhart CJ, Pierson TC. 2011. The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases. J. Virol. 85:12067-12072.
59. Randolph VB, Winkler G, Stollar V. 1990. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450-458.
60. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
61. Pitcher TJ, Gromowski GD, Beasley DW, Barrett AD. 2012. Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology 422:386-392.
62. Gromowski GD, Roehrig JT, Diamond MS, Lee JC, Pitcher TJ, Barrett AD. 2010. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407:237-246.
63. Zhang S, Bovshik EI, Maillard R, Gromowski GD, Volk DE, Schein CH, Huang CY, Gorenstein DG, Lee JC, Barrett AD, Beasley DW. 2010. Role ofBCloop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III. Virology 403:85-91.
64. Matsui K, Gromowski GD, Li L, Barrett AD. 2010. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. J. Gen. Virol. 91:2249-2253.
65. Matsui K, Gromowski GD, Li L, Schuh AJ, Lee JC, Barrett AD. 2009. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384:16-20.
66. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
67. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type-and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
68. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360.
69. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, Fremont DH, Kuhn RJ, Rossmann MG. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 103:12400-12404.
70. Pierson TC, Diamond MS. 2012. Degrees of maturity:the complex structure and biology of flaviviruses. Curr. Opin. Virol. 2:168-175.
71. Crill WD, Chang GJ. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78:13975-13986.
72. Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ. 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75:4002-4007.
73. Chu JJ, Rajamanonmani R, Li J, Bhuvanakantham R, Lescar J, Ng ML. 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86:405-412.
74. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412.
75. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusionassociated motif in gp41. Immunity 22:163-173.